11,552 views
The reclassification of zolpidem by Anvisa has brought significant changes for doctors and patients. José Roberto de Toledo and Talyta Vespa discuss the subject in this episode of UOL Prime. Based on recent data and patient reports, the podcast explores the impacts of this decision and the challenges in controlling the use of the drug.